



Press Release

For immediate release

London Technology Fund supports further successful fundraising by flu vaccine specialist ITS

“Bridging the technology equity gap”

LONDON, UK, 3 February 2009 – London Technology Fund (LTF), London’s specialist investor in new technology companies, today announced it has completed a further investment in Immune Targeting Systems Limited (ITS), a company developing synthetic vaccines for mutating viruses. LTF was the only UK investor in an international syndicate which has now invested £4.5m. The syndicate includes HealthCap (Sweden), Novartis Venture Fund (Switzerland), and Truffle Capital (France). The London Development Agency previously contributed an Exceptional Development Project award of £500,000 under the Grant for Research and Development scheme. This important investment will enable the Company to transition its lead vaccine programme into the clinic and strengthen its board and management team.

ITS’s novel vaccines target the prevention and treatment of major life-threatening viral infections of global impact, initially seasonal and pandemic influenza, and potentially followed by Hepatitis C and HIV/AIDS. Based on patented vaccine technology designed to target genetically diverse mutation-prone viruses, where cellular immunity is critical to disease protection, the vaccines should have broad efficacy across a wide range of virus strains and avoid the need to re-engineer the vaccine to target new virus strains. In the case of pandemic flu, it aims to offer governments the option of stockpiling vaccines which can be used as the first line of defence, giving time for strain-specific vaccines to be manufactured.

Carlton Brown, CEO of ITS, commented: *“We are delighted at the continued support of such a strong syndicate of specialist investors, including LTF. Their ongoing support has enabled us to reinforce our team further and continue the development of our technology to target these significant diseases”*.

David McMeekin, Chairman of LTF, said: *“We are pleased to be able to continue to support ITS as it develops its important vaccine platform and are impressed with the team that Carlton Brown has brought together”*.

Contact details

Immune Targeting Systems (ITS) Ltd **Carlton Brown, Founder and Chief Executive**
+44 (0)7970 944 454
London Bioscience Innovation Centre
2 Royal College Street
London NW1 0NH

London Technology Fund **David M^eMeekin, Chairman**
+44 (0)20 7247 6300
Company Guides Venture Partners Ltd
13 Christopher Street
London EC2A 2BS

- Notes to editors -

1. Immune Targeting Systems (ITS) www.its-innovation.co.uk

ITS is a London-based biotech company developing synthetic vaccines for mutating viruses. These novel vaccines will target the prevention and treatment of major life-threatening viral infections of global impact, including seasonal and pandemic influenza, Hepatitis-C and HIV/AIDS. The Company's lead programme is a universal influenza-A vaccine targeting all potential pandemic and seasonal flu strains (H1-H9; human, avian & swine) and is designed to remain unaffected by the ongoing mutation of the avian influenza virus. The Company has developed an integrated therapeutic T-cell vaccine platform which combines a proprietary vaccine antigen delivery technology with the rational design and validation of antigens suitable for vaccine delivery. The vaccine platform will permit the targeting of genetically diverse mutation prone viruses which cause human disease where protection is linked to effective antiviral cell mediated immunity. Many other viruses and diseases are also potential targets for this platform (HSV, RSV, Dengue, TB, Malaria, Ebola and Cancer). Its technology platform uniquely positions ITS in the field and potentially offers other important benefits. ITS's vaccines do not require adjuvant use, are fully synthetic obviating key manufacturing bottlenecks and do not rely on the use of a second and different vaccine technology to achieve a booster effect.

2. London Technology Fund www.londontechnologyfund.com

The London Technology Fund (LTF) is London's specialist investor in new technology companies. LTF is focused on the funding gap for new, high growth technology companies based in Greater London and bridges the gap by leading and building a syndicate of investors or by completing the gap in an existing syndicate. It invests from £50,000 to over £1m in individual investment rounds, resulting in investment rounds from LTF and co-investors ranging from £100,000 to over £10m.

To date, LTF has completed 16 investments in seven companies, acting as a key investor to help secure over £18m of funding for London-based high technology companies. These investments range from a seed-stage software company raising a total of £355,000, where LTF invested alongside business angels, to a life science company raising £6m to support the development of technologies for the separation and analysis of biomolecules.

The London Technology Fund is funded by the London Development Agency and the European Regional Development Fund. It is managed by Company Guides Venture Partners Ltd, which is authorised and regulated by the Financial Services Authority.

- E N D -